Trial reportClinical and experimental immunology2004
Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease.
Trial report in Clinical and experimental immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 120 citations in OpenAlex.
- Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.World journal of gastroenterology · 2015Trial
- Chaperonin in health and disease.Molecular biomedicine · 2026Review
- Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions.Cell & bioscience · 2024Review
- Heat Shock Proteins in Behçet SyndromeBalkan medical journal · 2023Review
- Enhancing Regulatory T Cells to Treat Inflammatory and Autoimmune Diseases.International journal of molecular sciences · 2023Review
- An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease.PloS one · 2023Article
- Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.Pharmaceutics · 2022Review
- Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis.The Journal of pharmacology and experimental therapeutics · 2022Article
- Frenemies within: An Endocarditis Case in Behçet's Disease.Journal of personalized medicine · 2021Article
- Isolation and detection of a KDEL-tagged recombinant cholera toxin B subunit fromProcess biochemistry (Barking, London, England) · 2021Article
- Oral tolerance as antigen-specific immunotherapy.Immunotherapy advances · 2021Review
- Plant cell-made protein antigens for induction of Oral tolerance.Biotechnology advances · 2019Review
- LPS enhances CTB-INSULIN induction of IDO1 and IL-10 synthesis in human dendritic cells.Cellular immunology · 2019Article
- Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa.Toxins · 2017Review
- Oral administration of a recombinant cholera toxin B subunit promotes mucosal healing in the colon.Mucosal immunology · 2017Article
- Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Low doses of cholera toxin and its mediator cAMP induce CTLA-2 secretion by dendritic cells to enhance regulatory T cell conversion.PloS one · 2017Article
- Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes.Plant biotechnology journal · 2016Article
- Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.Biomaterials · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behcet's disease (BD) specific peptide (p336-351) was identified within the human 60 kD heat shock protein (HSP60). Oral p336-351 induced uveitis in rats which was prevented by oral tolerization with the peptide linked to recombinant cholera toxin B subunit (CTB). This strategy was adopted in a phase I/II clinical trial by oral administration of p336-351-CTB, 3 times weekly, followed by gradual withdrawal of all immunosuppressive drugs used to control the disease in 8 patients with BD. The patients were monitored by clinical and ophthalmological examination, as well as extensive immunological investigations. Oral administration of p336-351-CTB had no adverse effect and withdrawal of the immunosuppressive drugs showed no relapse of uveitis in 5 of 8 patients or 5 of 6 selected patients who were free of disease activity prior to initiating the tolerization regimen. After tolerization was discontinued, 3 of 5 patients remained free of relapsing uveitis for 10-18 months after cessation of all treatment. Control of uveitis and extra-ocular manifestations of BD was associated with a lack of peptide-specific CD4+ T cell proliferation, a decrease in expression of TH1 type cells (CCR5, CXCR3), IFN-gamma and TNF-alpha production, CCR7+ T cells and costimulatory molecules (CD40 and CD28), as compared with an increase in these parameters in patients in whom uveitis had relapsed. The efficacy of oral peptide-CTB tolerization will need to be confirmed in a phase III trial, but this novel strategy in humans might be applicable generally to autoimmune diseases in which specific antigens have been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.